$EOLS News

Evolus Enters Into Exclusive Licensing And Distribution Agreement With IBSA To Develop And Commercialize Profhilo In US

BTIG Reiterates Buy on Evolus, Maintains $13 Price Target

Evolus Files Prospectus To Offer Up To $250M Of Securities

Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. 2026 Q1 - Results - Earnings Call Presentation

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

Evolus, Inc. Q1 2026 Earnings Call Summary

Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally

Evolus Q1 Earnings Call Highlights

Evolus (EOLS) Q2 2025 Earnings Call Transcript

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Evolus Affirms FY2026 Sales Guidance of $327.000M-$337.000M vs $330.020M Est

Evolus Q1 Adj. EPS $(0.16) Misses $(0.13) Estimate, Sales $73.137M Beat $72.288M Estimate

How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions

Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference

Evolus to Report First Quarter Financial Results on May 4, 2026

How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)